DAPSONE tablets, USP – prescribing information, overdosage and methemoglobinemia section (2026)

Government Record · Everest Life Sciences; U.S. National Library of Medicine DailyMed · November 2, 2026

Everest Life Sciences et al., 2026-11-02: The dapsone label calls methylene blue 1-2 mg/kg intravenously the treatment of choice for dapsone-overdose methemoglobinemia, with an oral option of 3-5 mg/kg every 4-6 hours.

In normal and methemoglobin reductase deficient patients, methylene blue, 1-2 mg/kg of body weight, given slowly intravenously, is the treatment of choice.

4

Everest Life Sciences et al., 2026-11-02: The dapsone label calls methylene blue 1-2 mg/kg intravenously the treatment of choice for dapsone-overdose methemoglobinemia, with an oral option of 3-5 mg/kg every 4-6 hours. C2 and C3. Label holder Everest Life Sciences; SPL published 2026-11-02. Doses quoted from the label's OVERDOSAGE section: 1-2 mg/kg IV given slowly, effect complete in 30 minutes but may need repeating; oral 3-5 mg/kg every 4-6 hours for non-emergencies; 'Methylene blue reduction depends on G6PD and should not be given to fully expressed G6PD deficient patients.' This is a label statement (record field within a narrative section), quoted verbatim, confidence HIGH because it is a continuous passage. Study type: regulatory record.